Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: CONRAD Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662
View directory record Official record
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison of Tenofovir Vaginal Gel and Film Formulations

NCT02280109
View directory record Official record
Conditions
Healthy, HIV
Interventions
Tenofovir Gel, Tenofovir Film
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

NCT00561496
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

NCT01694407
View directory record Official record
Conditions
HIV
Interventions
Tenofovir (TFV) Alone Vaginal Tablet, Emtricitabine (FTC) Alone Vaginal Tablet, TFV and FTC Combined Vaginal Tablet, Placebo Vaginal Tablet
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
The Bronx, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772
View directory record Official record
Conditions
Hiv, HSV
Interventions
TAF/EVG Vaginal Insert
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Male Hormonal Contraceptive Development-ACY-5

NCT00161447
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

NCT01687218
View directory record Official record
Conditions
HIV
Interventions
Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older · Male only
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Contraceptives on Cervico-Vaginal Mucosa

NCT04814927
View directory record Official record
Conditions
Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions
Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study

NCT06274398
View directory record Official record
Conditions
Safety Issues
Interventions
TAF/EVG rectal insert, Matching placebo rectal insert
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue

NCT01347632
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Discharge
Interventions
Metronidazole
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

NCT01575405
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
Drug
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 18, 2026, 11:42 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% vaginal gel, HEC Placebo Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
15 Years to 17 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
The Bronx, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Contraceptive Effectiveness Trial of Cellulose Sulfate Gel

NCT00255294
View directory record Official record
Conditions
Contraception
Interventions
Cellulose sulfate vaginal gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2005 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

NCT01232803
View directory record Official record
Conditions
Rectal Microbicides
Interventions
Tenofovir 1% gel, 2% N-9 gel, HEC Placebo gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

NCT03279120
View directory record Official record
Conditions
Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
Interventions
TFV/LNG IVR, Placebo
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse

NCT04195776
View directory record Official record
Conditions
HIV/AIDS, HIV Prevention
Interventions
Tenofovir Douche
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

NCT00408538
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781 microbicide gel (0.1% and 0.25%), placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 4 Interventional Results available

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

NCT01448616
View directory record Official record
Conditions
Herpes Simplex Type II
Interventions
TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 18, 2026, 11:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Residence Time of Biomarkers of Semen Exposure

NCT00984555
View directory record Official record
Conditions
Semen Exposure
Interventions
Not listed
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Coital Pharmacokinetics/Pharmacodynamics (PK/PD) of Tenofovir Gel

NCT01687205
View directory record Official record
Conditions
Pharmacokinetics of 1% Tenofovir Gel Following Coitus, Pharmacodynamics of 1% Tenofovir Gel Following Coitus
Interventions
1% Tenofovir Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 46 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel

NCT02309554
View directory record Official record
Conditions
Contraception
Interventions
SILCS diaphragm used with ContraGel, SILCS diaphragm used with 3% Nonoxynol-9, SILCS diaphragm
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Postcoital Testing of the SILCS Diaphragm

NCT00561613
View directory record Official record
Conditions
Contraceptive Device
Interventions
SILCS and lubricant, SILCS and spermicide
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

NCT01593124
View directory record Official record
Conditions
Vaginal Inflammation, Vaginal Infections
Interventions
Imiquimod, Placebo, Nonoxynol-9
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 18, 2026, 11:42 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Contraceptive Effectiveness and Safety of the SILCS Diaphragm

NCT00578877
View directory record Official record
Conditions
Contraception
Interventions
SILCS Diaphragm, Nonoxynol-9 Gel, Buffer Gel
Device · Combination Product
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 40 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 18, 2026, 11:42 PM EDT